Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders

Hadassah Medical Center

Status: Unknown

Conditions: Infertility

Treatments: Drug: Ovitrelle

Study type: Interventional

Funder types: Other

Identifiers

NCT01205009

hCGpoorresp-HMO-CTIL

Details and patient eligibility

About

In an era of delayed fertility plans, there is increasing need for fertility treatment in older women with poor response. Human chorionic gonadotropin (hCG) supplementation prior to treatment, as a thecal stimulant, may improve folliculogenesis and ovarian response.

Enrollment: 100 estimated patients

Sex: Female

Ages: 40 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• women >39 years on IVF treatment

Exclusion criteria

• polycystic ovary syndrome
• Any allergy to injection of human chorionic gonadotropin before

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

100 participants in 2 patient groups

Ovitrelle supplemantation

Active Comparator group

Description:

The women will be given 250 mcg of Ovitrelle prior to their IVF cycle

Treatment:

Drug: Ovitrelle

no Ovitrelle supplementation

No Intervention group